Wisconsin is currently home to 1287 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
NCT02688517
Recruiting
This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
08/03/2023
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Malignant Neoplasm
Register for Updates
Dose Frequency RCT on DTTC in Children With CAS
NCT05675306
Recruiting
Childhood apraxia of speech (CAS) is a pediatric motor-based speech sound disorder that requires a specialized approach to intervention (Maas et al., 2014). The extant literature on the treatment of CAS commonly recommends intensive treatment using a motor-based approach, with some of the best evidence supporting the use of Dynamic Temporal and Tactile Cueing (DTTC; Strand, 2020). To date, a rigorous and systematic comparison of high and low dose frequency has not been undertaken for DTTC, resul... Read More
Gender:
ALL
Ages:
Between 30 months and 95 years
Trial Updated:
07/25/2023
Locations: Marquette U, Milwaukee, Wisconsin
Conditions: Childhood Apraxia of Speech
Register for Updates
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT05207709
Recruiting
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 site... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Unv. Wisconsin, Madison, Wisconsin
Conditions: Metastatic Breast Cancer
Register for Updates
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NCT05794880
Recruiting
This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
06/09/2023
Locations: Children's Wisconsin, Milwaukee, Wisconsin
Conditions: Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia, Acute Lymphoblastic Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia With Crisis of Blast Cells, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Burkitt Leukemia, Lymphoma After Relapse, Other Malignant Hematologic Diseases in Remission
Register for Updates
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
NCT05893420
Recruiting
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which patients are at increased risk for clinical deterioration. The algorithm specifically predicts imminent death or the need for intensive care unit (ICU) transfer. Within the eCART interface, clinical tea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2023
Locations: University of Wisconsin Health, Madison, Wisconsin
Conditions: Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability, COVID-19, Cardiac Arrest, Clinical Deterioration
Register for Updates
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
NCT03546582
Recruiting
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2023
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Register for Updates
Effect of Plasma Ceramides on Peripheral Vascular Function
NCT05107869
Recruiting
The goal of this clinical trial is to determine the effect of elevated plasma ceramides on peripheral vascular function. Subjects will consume a high fat meal consisting of long chain fatty acids (to increase plasma ceramides) or medium chain fatty acids (control). Subjects' vascular function will be assessed with laser Doppler flowmetry to measure their artery function and with the CytoCam device to assess their peripheral microvascular endothelial function.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
05/15/2023
Locations: Froedtert Hospital, Wauwatosa, Wisconsin
Conditions: Peripheral Vascular Disease, Lipid Disorder, Endothelial Dysfunction
Register for Updates
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
NCT04565015
Recruiting
The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).
Gender:
ALL
Ages:
Between 2 years and 16 years
Trial Updated:
05/15/2023
Locations: University of Wisconsin, Milwaukee, Wisconsin
Conditions: Primary Immune Deficiency
Register for Updates
The Feasibility and Examination of the Effects of Floatation-based REST on a Community Sample With PTSD
NCT04368689
Recruiting
This project is being done to explore the effects floating has on individuals who have a history of trauma with stress related symptoms.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/08/2023
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Post-Traumatic Stress Disorders
Register for Updates
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-011 - University of Wisconsin Health University Hospital, Madison, Wisconsin
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: Medical College of Wisconsin - Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: American Family Children's Hospital University of Wisconsin, Madison, Wisconsin
Conditions: Langerhans Cell Histiocytosis
Register for Updates